{"filings":[{"id":1195316,"accession_number":"0001321732-26-000030","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-06-22T20:19:00+00:00","items":["5.07"],"status":"ready","headline":"Penumbra shareholders elect all three Class II director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class II director nominees elected: Arani Bose (21.1M for), Bridget O'Rourke (23.8M for), Surbhi Sarna (24.2M for).","Ratification of PricewaterhouseCoopers as independent auditor approved with 29.2M for, 42,529 against.","Advisory vote on named executive officer compensation approved with 24.1M for, 762,612 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92081,"accession_number":"0001321732-26-000024","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Penumbra shareholders approve merger with Boston Scientific; vote 28.6M for, 85k against","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Special meeting held May 6, 2026; 28,665,933 shares present, quorum achieved.","Merger Proposal adopted: 28,564,786 for, 85,334 against, 15,813 abstain.","Advisory compensation proposal also approved: 27,811,605 for.","Adjournment proposal deemed unnecessary after merger approval.","Closing remains subject to regulatory clearances, including HSR and non-U.S. antitrust."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92080,"accession_number":"0001321732-26-000018","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 revenue $374.8M (+15.6% YoY); net income $32.6M; no guidance due to pending BSX acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $374.8M, up 15.6% YoY; thrombectomy $253.9M (+12.1%), embolization & access $120.8M (+23.8%).","Gross margin 67.6% (+1.0 pp); operating income $38.2M; net income $32.6M.","Operating expenses include $9.4M acquisition-related costs for pending Boston Scientific deal.","No FY2026 guidance provided due to pending acquisition by Boston Scientific (NYSE: BSX)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":374758000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102630,"accession_number":"0001321732-26-000006","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q4 revenue $385.4M (+22.1%); operating income $59.2M; FY25 rev $1.4B (+17.5%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $385.4M for Q4, up 22.1% YoY (20.9% constant currency). US Thrombectomy $203.1M (+12.4%).","Gross margin 68.0% vs 66.8% a year ago; operating margin 15.4%.","Net income $47.3M; adjusted EBITDA $79.1M (20.5% margin).","Full year revenue $1,403.7M, up 17.5%; net income $177.7M; adjusted EBITDA $266.8M.","Embolization & access revenue grew 37.0% in Q4; international revenue up 27.7% (21.9% constant currency)."],"consensus_eps_estimate":null,"consensus_eps_actual":4.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1403665000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102629,"accession_number":"0000950103-26-000523","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Boston Scientific to acquire Penumbra: $374 cash or 3.8721 BSX shares per share; 73% cash/27% stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Penumbra holders elect $374 cash or 3.8721 BSX shares per share; proration targets 73.26% cash/26.74% stock.","Termination: Penumbra pays $525M if it accepts superior offer; Boston Sci pays $900M if antitrust fails.","Closing subject to Penumbra stockholder vote, HSR and foreign antitrust clearance, S-4 effectiveness, NYSE listing.","Preliminary Q4/FY2025 results released; audited financials pending, specific figures not in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118866,"accession_number":"0001321732-25-000108","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q3 revenue $354.7M (+17.8% YoY); full-year guidance raised to $1.375-1.380B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $45.9M; adjusted EBITDA $66.7M (18.8% margin).","U.S. Thrombectomy revenue $192.0M (+18.5%); U.S. VTE revenue up 34% YoY.","Gross margin improved to 67.8% vs 66.5% a year ago; operating margin 13.8%.","Full-year 2025 revenue guidance increased to $1.375B-$1.380B (15-16% growth).","Total revenue $354.7M (+17.8% or +16.9% constant currency); U.S. revenue +21.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1018280000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135406,"accession_number":"0001321732-25-000101","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Penumbra promotes Shruthi Narayan to President, CEO remains Elsesser","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shruthi Narayan, former President Interventional, becomes President effective Sept 1, 2025; reports to CEO Adam Elsesser.","Adam Elsesser, who previously held President role, continues as Chairman and CEO.","Narayan received equity grant of ~$2.5M in RSUs vesting over 4 years.","Spouse is CEO of N28 Technologies; Penumbra paid N28 ~$2M since Jan 2024 under approved agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135405,"accession_number":"0001321732-25-000097","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q2 revenue $339.5M (+13.4% YoY); net income $45.3M vs prior-year loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $339.5M, +13.4% YoY; U.S. Thrombectomy $188.5M (+22.6%); U.S. VTE +42%.","Net income $45.3M vs loss from operations of $81.0M in Q2 2024; operating margin 12.0%.","Adjusted EBITDA $61.4M (18.1% margin); gross margin improved to 66.0% from 54.4% (ex $33.4M one-time charge)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":663595000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152391,"accession_number":"0001321732-25-000093","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Penumbra shareholders approve board declassification and supermajority elimination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declassification approved by 31,773,328 votes; phase-in over 3 years, fully declassified by 2028.","Supermajority voting requirement eliminated by 31,755,837 votes; replaced with majority standard.","Class I directors Janet Leeds and Thomas Wilder elected with 29.9M and 27.2M votes for, respectively.","Advisory say-on-pay approved with 31.1M votes for (97.7% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152390,"accession_number":"0001321732-25-000085","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 2025 revenue $324.1M (+16.3% YoY); net income $39.2M; raises U.S. thrombectomy guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $324.1M (+16.3% YoY); U.S. Thrombectomy $187.9M (+25.0%).","Net income $39.2M; adjusted EBITDA $59.6M (18.4% margin).","Operating income $40.4M (12.4% margin); gross margin improved to 66.6% from 65.0%.","Raises U.S. Thrombectomy growth guidance to 20-21% YoY (from 19-20%); rev guidance reaffirmed $1.34-$1.36B.","International revenue down 2.5% YoY (-0.1% constant currency)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":324140000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171227,"accession_number":"0001321732-25-000036","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Penumbra director Don Kassing to retire April 1, 2025 after 17 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Don Kassing, board member since 2008 and Presiding Director since 2015, will retire effective April 1, 2025.","Kassing's retirement is not due to any disagreement with Penumbra.","No replacement for the board seat has been announced.","Kassing previously served as President Emeritus and President of San Jose State University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171226,"accession_number":"0001321732-25-000010","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q4 adjusted revenue $321.3M (+13%); U.S. thrombectomy up 27%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted revenue (excl. Italian payback) Q4 $321.3M, up 12.9% YoY; reported revenue $315.5M (+10.8%).","GAAP net income Q4 $33.7M (10.7% margin); full-year net income $14.0M.","Adjusted EBITDA Q4 $63.7M (19.8% margin); full-year $171.0M (14.2% margin).","U.S. thrombectomy products grew 27.3% in Q4; international thrombectomy revenue declined 13.9% adjusted.","Full-year adjusted revenue $1,200.4M, up 13.4% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1194615000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188200,"accession_number":"0001321732-24-000116","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q3 revenue $301M (+11.1% YoY); U.S. thrombectomy up 21.2%; raises segment guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $301.0M, +11.1% YoY; net income $29.5M; adjusted EBITDA $56.7M (18.8% margin).","U.S. thrombectomy revenue $162.1M, +21.2% YoY; VTE franchise grew 32% vs Q3 2023.","GAAP operating income $35.4M vs $12.6M in Q3 2023; non-GAAP operating income $40.3M.","Full-year 2024 revenue reaffirmed $1.18-1.20B; U.S. thrombectomy growth expectation raised to 24-25% from 23-25%.","Wind down of Immersive Healthcare incurred $5M in one-time expenses during Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":879097000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204689,"accession_number":"0001321732-24-000090","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Penumbra announces $200M share repurchase authorization, $100M accelerated buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $200M in stock repurchases through July 31, 2025.","$100M accelerated share repurchase (ASR) with JPMorgan Chase initiated on Aug 12, 2024.","Initial delivery of ~474,000 shares on Aug 13, 2024; final settlement expected Q3 2024.","ASR funded with cash on hand; will reduce diluted share count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204688,"accession_number":"0001321732-24-000086","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).","GAAP operating loss $81.0M includes $110.3M non-cash impairment/write-down on Immersive Healthcare assets.","Non-GAAP income from operations $31.7M vs $20.3M YoY; adjusted EBITDA $46.3M (15.5% margin).","Cash/marketable investments increased $26.2M from Q1, driven by non-GAAP profitability and working capital.","Global embolization & access revenue fell 3.1% YoY to $95.9M, with international down 10.8%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":578058000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221535,"accession_number":"0001321732-24-000075","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Penumbra stockholders elect two Class III directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adam Elsesser and Harpreet Grewal elected as Class III directors with ~86% of votes cast.","Ratification of PwC as independent auditor for FY2024 approved: 35.1M for, 57.5K against.","Advisory vote on executive compensation passed with 29.2M for, 2.1M against.","Total shares outstanding entitled to vote: 38,757,817; 35,255,367 voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221534,"accession_number":"0001321732-24-000058","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 revenue $278.7M (+15.4% YoY); U.S. thrombectomy up 35.2%; reaffirms FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $278.7M, up 15.4% YoY (15.2% constant currency); U.S. thrombectomy $150.3M, +35.2%.","GAAP operating income $12.1M vs $8.0M YoY; non-GAAP operating income $19.3M.","Adjusted EBITDA $37.6M (13.5% margin); cash & investments rose $24.3M sequentially.","FY2024 guidance reaffirmed: total revenue growth 16-20%, U.S. thrombectomy growth 27-30%.","Gross margin improved to 65.0% from 62.6% on favorable product mix and productivity."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":278655000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241067,"accession_number":"0001321732-24-000042","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Penumbra dismisses Deloitte, appoints PwC as auditor for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche dismissed as independent auditor effective March 17, 2024.","PricewaterhouseCoopers appointed as new auditor for fiscal year ending Dec 31, 2024.","Deloitte's reports on 2023 and 2022 financials contained no adverse opinion or qualification.","No disagreements or reportable events occurred during 2023, 2022, or interim period through March 17, 2024.","Deloitte has provided a letter agreeing with the company's disclosures, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241066,"accession_number":"0001321732-24-000023","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q4 revenue $284.7M (+28.7%); thrombectomy sales up 42.4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $284.7M in Q4 2023, up 28.7% YoY; full-year $1,058.5M, up 25.0%.","Thrombectomy product revenue $190.8M in Q4 (+42.4%); full-year $677.3M (+32.5%).","Net income $54.2M in Q4; adjusted EBITDA margin 18.8%; cash and investments up $40.3M.","FY 2024 guidance: total revenue growth 16-20%, US thrombectomy growth 27-30%, gross margin +100-150bps.","Non-GAAP operating income $37.4M in Q4; full-year $101.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1058522000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258549,"accession_number":"0001321732-23-000126","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q3 revenue $270.9M (+26.8% YoY); raises full-year revenue guidance to $1.05B-$1.07B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $270.9M (+26.8% YoY, +25.9% constant currency); thrombectomy products revenue $179.1M (+38.0% YoY).","Income from operations $12.6M; non-GAAP income from operations $33.2M. Net income $9.2M; adjusted EBITDA $51.5M (19.0% margin).","Gross margin improved to 65.6% from 63.3% YoY, driven by favorable product mix and higher volume.","Recorded $18.2M one-time expense for acquired IPR&D; total operating expenses 60.9% of revenue.","Q4 2023 revenue growth expected 28%-31% YoY; full year 2023 revenue guidance raised to $1.05B-$1.07B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":773843000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275849,"accession_number":"0001321732-23-000091","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K/A","filed_at":"2023-08-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Penumbra board chooses annual Say-on-Pay votes until 2029","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["At May 31, 2023 annual meeting, shareholders approved advisory vote for annual Say-on-Pay frequency.","Board considered results and adopted annual Say-on-Pay votes consistent with shareholder recommendation.","Next advisory vote on frequency of Say-on-Pay expected no later than the 2029 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275850,"accession_number":"0001321732-23-000086","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q2 revenue $261.5M +25.5% YoY; raises FY2023 guidance to $1.05-1.07B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $261.5M (+25.5% YoY constant currency), U.S. 71%, international 29%.","Vascular segment $152.7M (+23.6%), neuro segment $108.8M (+28.3%).","GAAP operating income $17.9M vs loss $0.1M; non-GAAP operating income $20.3M vs $1.6M.","Gross margin 63.8% vs 64.3% YoY; R&D $21.5M, SG&A $127.4M.","FY2023 revenue guidance raised to $1.05-1.07B (24-26% growth); vascular to outpace, neuro below."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":502897000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293464,"accession_number":"0001321732-23-000072","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Penumbra shareholders elect three Class II directors, ratify auditor, and approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Arani Bose, Bridget O'Rourke, and Surbhi Sarna as Class II directors with strong majority support (over 25.8M votes for each).","Ratified Deloitte & Touche as independent auditor for FY2023: 35,135,454 for, 79,089 against, 7,956 abstain.","Advisory vote on named executive officer compensation approved: 26,815,488 for, 4,084,213 against, 21,240 abstain.","Advisory vote on frequency of future say-on-pay set to annual: 30,831,408 for one year, 16,852 for two years, 63,352 for three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293463,"accession_number":"0001321732-23-000060","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 revenue $241.4M (+18.4%); raises FY 2023 guidance to $1.04-1.06B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $241.4M (+18.4% YoY, +19.7% constant currency); vascular $142.8M, neuro $98.5M.","Gross margin 62.6%; operating income $8.0M vs loss of $4.0M YoY.","Non-GAAP operating income $10.4M vs non-GAAP loss of $2.3M YoY.","Raised full-year 2023 revenue guidance: $1.04B to $1.06B (23% to 25% growth).","Vascular growth expected slightly above guidance range; Neuro growth below."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":241398000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314091,"accession_number":"0001321732-23-000032","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q4 2022 revenue $221.2M, up 8.4% YoY; operating income $4.8M vs loss $40.1M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 revenue $221.2M (+8.4% YoY, +10.5% constant currency); full year $847.1M (+13.3%).","US revenue Q4 $157.1M (+8.8%); vascular product revenue $129.7M (+14.2%), neuro $91.5M (+1.2%).","Gross margin improved to 62.6% from 61.5% YoY.","Operating income $4.8M vs loss $40.1M in Q4 2021; non-GAAP operating income $7.2M vs $2.5M.","Full year revenue $847.1M, up 13.3% YoY; US revenue $591.7M (+12.1%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":847133000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332531,"accession_number":"0001321732-22-000103","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q3 rev $213.7M (+12.4%); cuts FY22 guide to $840-845M on Flash delay, FX headwind","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $213.7M, +12.4% YoY (+15.1% constant currency); vascular +17%, neuro +6.7%.","GAAP operating income $5.4M vs $8.8M prior year; non-GAAP op income $7.8M.","FY2022 revenue guidance reduced to $840-845M; cites Lightning Flash launch delay to Q1 2023 and $4-6M FX headwind.","Expects to reach $1B revenue in 2023.","Gross margin 63.3% vs 63.1% prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":625917000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350002,"accession_number":"0001321732-22-000079","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Penumbra adopts proxy access bylaw allowing 3% holders to nominate directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Second Amended and Restated Bylaws effective August 1, 2022, adding proxy access.","Eligible stockholders (or groups up to 20) with at least 3% ownership for 3 years may nominate directors.","Maximum nominees: greater of 25% of board seats or 2 directors; reduction applies if proxy-access-elected director stands for reelection.","Proxy access first available for the 2023 annual meeting; conforming changes to nomination notice requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350001,"accession_number":"0001321732-22-000076","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q2 revenue $208.3M (+13.1% YoY); GAAP operating loss vs prior-year income","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $208.3M, up 13.1% (15.3% constant currency); vascular $123.5M (+22.7%), neuro $84.8M (+1.5%).","GAAP operating loss of $0.1M vs income $10.3M in Q2 2021; non-GAAP operating income $1.6M (excl. Sixense amort.).","Gross margin 64.3% vs 64.4% prior; SG&A expenses rose to $114.6M from $90.6M.","FY2022 revenue guidance maintained at $860M-$875M; expects lower end due to FX; constant currency growth 15-17%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":412239000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367124,"accession_number":"0001321732-22-000061","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Penumbra annual meeting results: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Kassing, Leeds, Wilder elected; votes for/withheld: 25.6M/4.4M, 22.7M/7.3M, 25.7M/4.3M.","Ratification of Deloitte as auditor: 34.3M for, 79.7K against, 6.9K abstentions.","Advisory say-on-pay approved: 27.3M for, 2.6M against, 11.5K abstentions (broker non-votes 4.4M).","Total shares voted: 34.4M of 37.7M outstanding (91.3% participation)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367123,"accession_number":"0001321732-22-000051","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 2022: Revenue up 20.5% to $203.9M; operating loss of $4.0M vs income of $13.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $203.9M, up 20.5% YoY (21.8% constant currency).","Vascular sales $122.8M (+37.7%); neuro $81.1M (+1.3%).","Gross margin 62.5% vs 65.8% Q1 2021, impacted by labor/logistics costs.","Operating loss $4.0M vs operating income $13.5M in Q1 2021.","SG&A expense $110.9M, up from $79.8M, driving swing to loss."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":203895000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367122,"accession_number":"0001321732-22-000037","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Penumbra EVP and Chief Business Officer Lynn Rothman to depart May 2, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lynn Rothman, EVP and Chief Business Officer, notified Penumbra of her departure effective May 2, 2022.","Departure to start a non-profit organization focused on education.","No replacement named as of the filing date.","Role includes oversight of business development and strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386502,"accession_number":"0001321732-22-000016","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q4 2021 revenue $204M (+22% YoY); GAAP op loss $40.1M, adjusted op income $2.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $204.0M (+22.2% YoY; +23.0% constant currency); US $144.5M (+23.7%).","Vascular revenue $113.6M (+30.4%); neuro revenue $90.4M (+13.3%).","GAAP operating loss $40.1M; non-GAAP op income $2.5M excluding $25.8M Sixense accelerated vesting and $15.0M Thunderbolt R&D milestone.","Full year 2021 revenue $747.6M (+33.4%); non-GAAP op income $40.1M vs prior year loss of $22.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":747590000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386501,"accession_number":"0001321732-22-000010","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Penumbra denies being in discussions with Shockwave Medical for a business combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Penumbra issued statement on Jan 10, 2022 that it is not in discussions with Shockwave Medical regarding a business combination or similar transaction.","Statement made in response to media reports published prior to a large industry conference.","Company reiterates practice not to comment on rumors or market speculation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404409,"accession_number":"0001321732-21-000106","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q3 revenue $190.1M (+26%), swings to operating profit; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $190.1M, +25.8% YoY (+25.6% constant currency); US 71%, international 29%.","Vascular segment $105.5M (+40.3%); Neuro segment $84.7M (+11.5%).","Gross margin 63.1% vs 60.2%; operating income $8.8M vs loss of $20.2M a year ago.","Full-year 2021 revenue guidance raised to $735M-$740M from prior $720M-$730M.","R&D expense fell to $16.7M from $34.9M; SG&A rose to $94.4M from $76.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":543579000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404408,"accession_number":"0001321732-21-000094","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2021-10-07T23:59:59+00:00","items":["2.01","3.02"],"status":"ready","headline":"Penumbra completes acquisition of Sixense Enterprises for ~$300M in stock and options","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Oct 1, 2021; Sixense becomes wholly owned subsidiary of Penumbra.","Consideration: 661,877 Penumbra shares valued at $185.9M (VWAP $280.88) plus cash for fractional shares.","Options to purchase Sixense stock exchanged for options to buy 447,017 Penumbra shares valued at $114.1M.","Penumbra and Sixense previously partners in MVI Health Inc., a VR healthcare joint venture formed in 2017.","Penumbra purchased additional 40% of MVI from Sixense in Aug 2018 for $20M plus potential $4.5M anti-dilution payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423410,"accession_number":"0001321732-21-000082","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2021-09-22T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Penumbra enters M&A with Sixense; issues ~600K shares + options worth ~$300M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issues ~600,000 shares of common stock valued at ~$170 million based on $280.88 VWAP.","Grants fully vested options for ~520,000 shares valued at ~$130 million to Sixense service providers.","Merger expected to close on or about October 1, 2021; Sixense to become wholly owned subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423409,"accession_number":"0001321732-21-000059","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q2 revenue $184.3M (+75.3% YoY); raises FY2021 guidance to $720-730M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $184.3M (+75.3% YoY); vascular $100.7M (+117.6%), neuro $83.6M (+42.0%).","Operating income of $10.3M vs. operating loss of $17.6M in Q2 2020.","Gross margin improved to 64.4% from 61.8%.","Full-year 2021 revenue guidance raised to $720-730M from $695-705M (28-30% growth).","No EPS figure provided in release."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":353462000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}